NCT04407845
Atrial Fibrillation in Patients Receiving Ibrutinib No drug interventions Not Available Not Available unknown_status NCT02020109
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia No drug interventions Not Available Not Available withdrawn NCT01246557
Study Assessing Safety and Efficiency of the Lenalidomide and Dexamethasone Combination in Patients With Chronic Lymphatic Leukemia (CLL) Relapsing or Resistant to Treatment treatment 1 / 2 completed NCT02802943
iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL treatment 2 completed NCT01809847
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation treatment 2 completed NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma treatment 2 active_not_recruiting NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies other Not Available recruiting NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) treatment 2 recruiting NCT02267590
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib No drug interventions Not Available Not Available unknown_status NCT06357754
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy Not Available Not Available recruiting NCT03582098
Clinical Outcomes and Routine Management of Adults With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland Not Available Not Available completed NCT02164071
Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies No drug interventions Not Available Not Available completed NCT00802737
Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) treatment 4 completed NCT01446900
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma treatment 2 terminated NCT01805375
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies No drug interventions treatment 1 completed NCT01127542
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial treatment 2 terminated NCT00410163
Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients treatment 2 completed NCT01678430
A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment treatment 3 unknown_status NCT00824265
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia treatment 3 completed NCT02933320
BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia treatment 1 / 2 completed NCT01110031
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects other 1 completed NCT01039376
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy treatment 3 terminated NCT00292760
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion treatment 2 completed NCT01453062
Phase IV Observational Study in Chronic Lymphocytic Leukemia Not Available Not Available completed NCT00748189
Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia treatment 3 terminated NCT01563055
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia treatment 2 completed NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies treatment 1 / 2 not_yet_recruiting NCT01832597
Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders No drug interventions Not Available Not Available completed NCT04763083
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies No drug interventions treatment 1 recruiting NCT00349349
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab treatment 2 completed NCT01597219
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers No drug interventions treatment 2 completed NCT00751296
Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL) treatment 2 terminated NCT01520922
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) treatment 2 completed NCT01077622
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia treatment 2 completed NCT00457782
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma No drug interventions treatment 1 completed NCT00504491
R-CHOP and Alemtuzumab in Patients With Chronic Lymphocytic Leukemia treatment 2 withdrawn NCT01659255
Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL treatment 1 completed NCT05645172
Retention Rate of Acalabrutinib in a Non-interventional Setting No drug interventions Not Available Not Available recruiting NCT02273856
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL) No drug interventions Not Available Not Available terminated NCT02920697
Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma treatment 1 completed NCT01279252
CLL Empirical Antibiotic Regimen treatment 2 completed NCT03852407
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning treatment 2 recruiting NCT01518959
The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases treatment 3 terminated NCT04608318
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) treatment 3 active_not_recruiting NCT03804372
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide treatment 2 unknown_status NCT04515238
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL treatment 2 active_not_recruiting NCT03787264
Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL treatment 2 completed NCT00788684
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers treatment 1 active_not_recruiting NCT00406809
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies treatment 1 / 2 completed NCT04883749
Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL treatment 2 active_not_recruiting NCT03766763
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A treatment 2 recruiting NCT05350826
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia No drug interventions other Not Available recruiting NCT04512105
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia treatment 1 active_not_recruiting NCT05517265
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) Not Available Not Available recruiting NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) treatment 3 recruiting NCT06073821
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) treatment 3 recruiting NCT06506643
Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms treatment 1 / 2 recruiting NCT01168921
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT01675102
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL) No drug interventions Not Available Not Available completed NCT05246345
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available recruiting NCT00546793
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL treatment 1 / 2 completed NCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders treatment 2 completed NCT03283137
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL treatment 1 active_not_recruiting NCT01199575
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT00021749
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 completed NCT04016636
A Study to Evaluate Impact of Ibrutinib on the Quality of Life (QOL) in Patients With Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available completed NCT01465334
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL treatment 2 terminated NCT03639324
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL No drug interventions treatment 1 withdrawn NCT02362035
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies treatment 1 / 2 active_not_recruiting NCT03524235
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL treatment 1 active_not_recruiting NCT04806035
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia treatment 1 terminated NCT03868722
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment prevention 2 / 3 recruiting NCT05316831
Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia No drug interventions prevention 4 completed NCT04746092
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 No drug interventions Not Available Not Available unknown_status NCT06557304
The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in China No drug interventions Not Available Not Available not_yet_recruiting NCT02377869
Heavy Light Chain in Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT03919214
Hypertension Management in Cancer Patients No drug interventions supportive_care Not Available terminated NCT00628238
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) treatment 2 unknown_status NCT01191190
Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) treatment 2 completed NCT01703364
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL treatment 1 / 2 completed NCT06489184
The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China Not Available Not Available not_yet_recruiting NCT03231579
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study No drug interventions Not Available Not Available completed NCT05869279
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia No drug interventions treatment 1 / 2 recruiting NCT00792077
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue treatment 2 completed NCT01862445
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients No drug interventions Not Available Not Available unknown_status NCT05610228
Study of the Metabolism in the Lymphatic Niche of CLL No drug interventions Not Available Not Available recruiting NCT02046928
Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions treatment 2 terminated NCT04640909
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients No drug interventions basic_science Not Available recruiting NCT03572634
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL treatment 1 / 2 terminated NCT01397916
Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) No drug interventions Not Available Not Available completed NCT01532635
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives treatment 2 terminated NCT02229422
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) treatment 1 / 2 active_not_recruiting NCT04923048
A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. No drug interventions treatment 1 / 2 recruiting NCT02828774
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia No drug interventions Not Available Not Available unknown_status NCT00535873
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older treatment 2 completed NCT04694560
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma No drug interventions Not Available Not Available withdrawn NCT04639362
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD. treatment 2 active_not_recruiting NCT00185692
Allogeneic Transplantation From Related Haploidentical Donors treatment 2 completed NCT02863692
Registry of the German CLL Study Group No drug interventions Not Available Not Available recruiting NCT03997968
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT03113695
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome treatment 1 completed NCT00533923
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders treatment 2 completed NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL treatment 2 withdrawn NCT03294980
Chronic Lymphoid Leukaemia Observatory in Finistere Area, France No drug interventions Not Available Not Available recruiting